Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris Nagelmeier

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Der Pathologe|December 21, 2020
ISH-based HER2 diagnosticsJosef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Der Pathologe|October 1, 2020
[ISH-based HER2 diagnostics]Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 26, 2015
Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization dataOliver C Stoss, Andreas Scheel, Iris Nagelmeier, et al.
Virchows Archiv : an International Journal of Pathology|August 15, 2022
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low statusJosef Rüschoff, Michael Friedrich, Iris Nagelmeier, et al.
Virchows Archiv : an International Journal of Pathology|July 29, 2010
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testingJosef Rüschoff, Manfred Dietel, Gustavo Baretton, et al.
Oncotarget|April 28, 2015
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancerHanna Styczen, Iris Nagelmeier, Tim Beissbarth, et al.
Neoplasia (New York, N.Y.)|April 13, 2012
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionStefanie Derer, Sven Berger, Martin Schlaeth, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Der Pathologe|December 21, 2020
ISH-based HER2 diagnosticsJosef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Der Pathologe|October 1, 2020
[ISH-based HER2 diagnostics]Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 26, 2015
Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization dataOliver C Stoss, Andreas Scheel, Iris Nagelmeier, et al.
Virchows Archiv : an International Journal of Pathology|August 15, 2022
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low statusJosef Rüschoff, Michael Friedrich, Iris Nagelmeier, et al.
Virchows Archiv : an International Journal of Pathology|July 29, 2010
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testingJosef Rüschoff, Manfred Dietel, Gustavo Baretton, et al.
Oncotarget|April 28, 2015
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancerHanna Styczen, Iris Nagelmeier, Tim Beissbarth, et al.
Neoplasia (New York, N.Y.)|April 13, 2012
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionStefanie Derer, Sven Berger, Martin Schlaeth, et al.
Pageof 1